z-logo
open-access-imgOpen Access
Switching on the green light for chimeric antigen receptor T‐cell therapy
Author(s) -
Mardiana Sherly,
Lai Junyun,
House Imran Geoffrey,
Beavis Paul Andrew,
Darcy Phillip Kevin
Publication year - 2019
Publication title -
clinical and translational immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.321
H-Index - 34
ISSN - 2050-0068
DOI - 10.1002/cti2.1046
Subject(s) - chimeric antigen receptor , reprogramming , context (archaeology) , cell therapy , cancer research , genetic enhancement , immune system , tumor microenvironment , immunology , transgene , antigen , t cell , adoptive cell transfer , biology , medicine , cell , gene , genetics , paleontology
Adoptive cellular therapy involving genetic modification of T cells with chimeric antigen receptor ( CAR ) transgene offers a promising strategy to broaden the efficacy of this approach for the effective treatment of cancer. Although remarkable antitumor responses have been observed following CAR T‐cell therapy in a subset of B‐cell malignancies, this has yet to be extended in the context of solid cancers. A number of promising strategies involving reprogramming the tumor microenvironment, increasing the specificity and safety of gene‐modified T cells and harnessing the endogenous immune response have been tested in preclinical models that may have a significant impact in patients with solid cancers. This review will discuss these exciting new developments and the challenges that must be overcome to deliver a more sustained and potent therapeutic response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here